Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...

GlobalData’s patient-based forecast predicts Tecvayli will reach a peak of $2.1bn in sales globally by 2030 in MM.

Johnson & Johnson announces positive Phase II results for Tecvayli in newly diagnosed multiple myeloma, with all patients ...

Johnson & Johnson (JNJ) announced new frontline data featuring TECVAYLI (teclistamab-cqyv) from two investigational studies in ...

Johnson & Johnson announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly diagnosed ...

Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in ...

Tecvayli joins Roche's recently-approved CD20xCD3 bispecific Lunsumio (mosunetuzumab) for follicular lymphoma – also approved in the EU ahead of the US – which is competing with Novartis ...

Tecvayli's approval is based on the results of the phase 1b MajesTEC-1 study which found that after the bispecific antibody achieved an overall response rate of 63% at the recommended dose of 1.5 ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced new frontline data featuring TECVAYLI®▼ (teclistamab) from two investigational studies in patients with newly diagnosed ...

Anita D'Souza, MD, discusses some of the potentially practice-changing data that were presented at the 2024 ASH Annual ...

The US Food and Drug Administration has approved Johnson & Johnson’s (J&J) supplemental Biologics Licence Application for TECVAYLI (teclistamab-cqyv), allowing for a reduced dosing frequency for ...

Teclistamab is an off-the-shelf (or ready to use) bispecific antibody. 6 Teclistamab, a subcutaneous injection, redirects T-cells through two cellular targets (BCMA and CD3) to activate the body's ...